Research Grants

Research Grants Awarded

To support work being done to find treatments and a cure, we have awarded 15 research grants to PKD researchers. We will spend nearly $2.4 million over the next two years on these grants. The awardees represent top researchers and physician scientists throughout the United States, as well as Canada and Italy.

Learn More

2014 Transplant GamesTransplant Games of America

The Transplant Games of America is a multi-sport festival event for transplant recipients and living donors. Are you participating in the games? Tell us which team you will be joining and which events you will be competing in so that we can be there to cheer you on!

Learn More

PKD News

Research Grants Awarded

April 14, 2014

To support work being done to find treatments and a cure, we have awarded 15 research grants to PKD researchers. We will spend nearly $2.4 million over the next two years on these grants. The awardees represent top researchers and physician scientists throughout the United States, as well as Canada and Italy.

Five of the research grants focus on the development of a treatment for PKD so our patients have something that will slow the progression of the disease. The remaining ten are discovery research, which focuses on understanding the way in which cysts develop or enlarge in PKD. This must be conducted in order to identify cell compounds and pathways before therapy development can be done.

Learn More


Otsuka Pharmaceutical's Samsca® Approved in Japan as the World's First Drug Therapy for ADPKD

March 24, 2014

(Tokyo, Japan) - Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Samsca® (generic name: tolvaptan) has been approved in Japan in 7.5-mg and 15-mg tablet forms for extended use for the additional indication of ADPKD. Also, the new dosage form of 30-mg Samsca tablets has received approval for the indication of ADPKD.

In Europe, as of December, 2013, an application for regulatory approval of tolvaptan in ADPKD had been received and is under review. In the United States, based on a review issued by the FDA, Otsuka is having continued discussions regarding supplementary data and the path forward for resubmission.

Read the full news release from Otsuka


Voices of PKD

Brightening the Future for PKD FamiliesBrianna Rodgers and her family

The spring, for many, signals a new start and a perfect time to set new goals for the rest of the year. For 21-year-old Brianna Rodgers of Grapevine, Texas, 2014 is her year to make a difference in the PKD community. "I just want to take the opportunity to do something good," she said.

Flash back one decade ­­– Rodgers was diagnosed with polycystic kidney disease (PKD) at just 11 years old, making her the youngest person in a family full of PKD patients to deal with the disease.

Read Brianna's Story

Sign Up for Our E-Newsletter

*
*

PKD National Convention

PKD National Convention: Better Together
The PKD National Convention 2014 will be held June 20-22 in Kansas City, Mo.

Learn More

Register Now

About PKD and the PKD Foundation

Polycystic kidney disease is one of the most common, life threatening genetic diseases affecting thousands in America and millions worldwide. Learn more about this disease and how we're working to end PKD.

About ARPKD

A relatively rare form of PKD, Autosomal recessive polycystic kidney disease (ARPKD) affects approximately 1 in 20,000 children, and often causes mortality in the first month of life. Learn what we're doing to fight ARPKD.

The PKD Foundation is a 501 (c)(3), 509 (a)(1) public charity.
National Headquarters: 8330 Ward Parkway, Suite 510, Kansas City, MO 64114. Phone: 1.800.PKD.CURE
©2014 PKD Foundation. Privacy Policy | Terms & Conditions

Founded in 1982, our vision is that one day,
no one will suffer the full effects of polycystic kidney disease.


International: Canada Canada  France France  Germany Germany  Italy Italy  Japan Japan  United Kingdom United Kingdom